JP2013534424A - 二本鎖ｒｎａによるアンドロゲン受容体の特異的阻害に対する方法と化合物 - Google Patents

二本鎖ｒｎａによるアンドロゲン受容体の特異的阻害に対する方法と化合物 Download PDF

Info

Publication number
JP2013534424A
JP2013534424A JP2013518760A JP2013518760A JP2013534424A JP 2013534424 A JP2013534424 A JP 2013534424A JP 2013518760 A JP2013518760 A JP 2013518760A JP 2013518760 A JP2013518760 A JP 2013518760A JP 2013534424 A JP2013534424 A JP 2013534424A
Authority
JP
Japan
Prior art keywords
strand
dsrna
nucleotides
isolated
target
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013518760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013534424A5 (https=
Inventor
ボブ， デール ブラウン，
ヘンリク， ティー ドゥーデック，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dicerna Pharmaceuticals Inc
Original Assignee
Dicerna Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dicerna Pharmaceuticals Inc filed Critical Dicerna Pharmaceuticals Inc
Publication of JP2013534424A publication Critical patent/JP2013534424A/ja
Publication of JP2013534424A5 publication Critical patent/JP2013534424A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2013518760A 2010-07-06 2011-07-01 二本鎖ｒｎａによるアンドロゲン受容体の特異的阻害に対する方法と化合物 Pending JP2013534424A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36175910P 2010-07-06 2010-07-06
US61/361,759 2010-07-06
PCT/US2011/042810 WO2012006241A2 (en) 2010-07-06 2011-07-01 Methods and compositions for the specific inhibition of androgen receptor by double-stranded rna

Publications (2)

Publication Number Publication Date
JP2013534424A true JP2013534424A (ja) 2013-09-05
JP2013534424A5 JP2013534424A5 (https=) 2014-08-14

Family

ID=45441760

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518760A Pending JP2013534424A (ja) 2010-07-06 2011-07-01 二本鎖ｒｎａによるアンドロゲン受容体の特異的阻害に対する方法と化合物

Country Status (6)

Country Link
US (2) US8927515B2 (https=)
EP (1) EP2591104A4 (https=)
JP (1) JP2013534424A (https=)
AU (1) AU2011276363A1 (https=)
CA (1) CA2804210A1 (https=)
WO (1) WO2012006241A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019526260A (ja) * 2016-09-01 2019-09-19 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 化学修飾された一本鎖ｒｎａ編集オリゴヌクレオチド
JP2022513662A (ja) * 2018-11-28 2022-02-09 バイオニア コーポレーション アンドロゲン受容体特異的配列を含む二本鎖オリゴヌクレオチド構造体、及びこれを含む脱毛予防及び発毛用組成物
WO2025254047A1 (ja) * 2024-06-06 2025-12-11 東亞合成株式会社 アンドロゲン受容体 ｒｎａ配列に基づく新規二本鎖ｒｎａ及びその利用

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100048913A1 (en) 2008-03-14 2010-02-25 Angela Brodie Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
ES2836128T3 (es) 2008-04-16 2021-06-24 Univ Johns Hopkins Método para determinar variantes del receptor de andrógenos en cáncer de próstata
AR092982A1 (es) * 2012-10-11 2015-05-13 Isis Pharmaceuticals Inc Modulacion de la expresion de receptores androgenicos
CA2893824A1 (en) 2012-12-14 2014-06-19 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
RU2015137617A (ru) 2013-03-14 2017-04-18 Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер Агенты, подавляющие андрогенные рецепторы, и их применение
US9458457B2 (en) * 2013-07-03 2016-10-04 Dicerna Pharmaceuticals, Inc. Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA
CN105636594A (zh) 2013-08-12 2016-06-01 托凯药业股份有限公司 使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
WO2015179404A1 (en) 2014-05-19 2015-11-26 The Johns Hopkins University Methods for identifying androgen receptor splice variants in subjects having castration resistant prostate cancer
CA2959336A1 (en) * 2014-08-25 2016-03-03 The Johns Hopkins University Methods and compositions related to prostate cancer therapeutics
EP3234134B1 (en) 2014-12-17 2020-05-27 ProQR Therapeutics II B.V. Targeted rna editing
CA2989384A1 (en) 2015-07-30 2017-02-02 Bayer Cropscience Aktiengesellschaft Methods and compositions for the control of rust fungi by inhibiting expression of the hxt1 gene
US20170306334A1 (en) * 2016-04-01 2017-10-26 Avidity Biosciences Llc Androgen receptor nucleic acids and uses thereof
WO2017220751A1 (en) 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
CA3043768A1 (en) 2016-11-29 2018-06-07 PureTech Health LLC Exosomes for delivery of therapeutic agents
EP3571300A1 (en) 2017-01-19 2019-11-27 ProQR Therapeutics II B.V. Oligonucleotide complexes for use in rna editing
KR102321426B1 (ko) * 2017-02-21 2021-11-05 올릭스 주식회사 남성형 탈모 표적 유전자의 발현을 억제하는 비대칭 siRNA
WO2019165242A1 (en) * 2018-02-23 2019-08-29 Paraskevi Giannakakou Assay for detection of androgen receptor variants
JP7478923B2 (ja) 2018-03-27 2024-05-08 ユニバーシティ オブ ロチェスター シュードウリジン化のための核酸分子
GB201808146D0 (en) 2018-05-18 2018-07-11 Proqr Therapeutics Ii Bv Stereospecific Linkages in RNA Editing Oligonucleotides
WO2025160224A1 (en) * 2024-01-24 2025-07-31 Arrowhead Pharmaceuticals, Inc. Rnai agents for inhibiting expression of androgen receptor (ar), compositions thereof, and methods of use
WO2025226946A1 (en) * 2024-04-24 2025-10-30 Cedric Francois Methods and compositions for the treatment of androgenic alopecia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164970A1 (en) * 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor
JP2007215481A (ja) * 2006-02-16 2007-08-30 Ehime Univ アンドロゲン受容体遺伝子に特異的なｓｉＲＮＡ
US20080014584A1 (en) * 2006-06-01 2008-01-17 Mayo Foundation For Medical Education And Research Modulating androgen receptor activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050170371A1 (en) * 2001-05-18 2005-08-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of 5-alpha reductase and androgen receptor gene expression using short interfering nucleic acid (siNA)
AU2003295600A1 (en) * 2002-11-14 2004-06-15 Dharmacon, Inc. Functional and hyperfunctional sirna
US20060257851A1 (en) * 2002-11-26 2006-11-16 Itzhak Bentwich Bioinformatically detectable group of novel viral regulatory genes and uses thereof
CA2559955C (en) 2004-03-15 2016-02-16 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded rna
US20070265220A1 (en) 2004-03-15 2007-11-15 City Of Hope Methods and compositions for the specific inhibition of gene expression by double-stranded RNA

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050164970A1 (en) * 2003-12-22 2005-07-28 University Of Kansas Medical Center Method for treating prostate cancer using siRNA duplex for androgen receptor
JP2007215481A (ja) * 2006-02-16 2007-08-30 Ehime Univ アンドロゲン受容体遺伝子に特異的なｓｉＲＮＡ
US20080014584A1 (en) * 2006-06-01 2008-01-17 Mayo Foundation For Medical Education And Research Modulating androgen receptor activity

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JPN6015029963; Ｂｉｏｃｈｅｍ．　Ｂｉｏｐｈｙｓ．　Ｒｅｓ．　Ｃｏｍｍｕｎ．，　２０１０，　Ｖｏｌ．　３９１，　ｐｐ．　１０７５-１０７９ *
JPN6015029964; ＰＬＯＳ　ｏｎｅ，　２００７，　Ｉｓｓｕｅ　１０，　ｅ１００６ *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019526260A (ja) * 2016-09-01 2019-09-19 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 化学修飾された一本鎖ｒｎａ編集オリゴヌクレオチド
JP7244922B2 (ja) 2016-09-01 2023-03-23 プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ 化学修飾された一本鎖ｒｎａ編集オリゴヌクレオチド
JP2022513662A (ja) * 2018-11-28 2022-02-09 バイオニア コーポレーション アンドロゲン受容体特異的配列を含む二本鎖オリゴヌクレオチド構造体、及びこれを含む脱毛予防及び発毛用組成物
JP2023113845A (ja) * 2018-11-28 2023-08-16 バイオニア コーポレーション アンドロゲン受容体特異的配列を含む二本鎖オリゴヌクレオチド構造体、及びこれを含む脱毛予防及び発毛用組成物
JP7625033B2 (ja) 2018-11-28 2025-01-31 バイオニア コーポレーション アンドロゲン受容体特異的配列を含む二本鎖オリゴヌクレオチド構造体、及びこれを含む脱毛予防及び発毛用組成物
US12569561B2 (en) 2018-11-28 2026-03-10 Bioneer Corporation Double stranded oligonucleotide construct comprising androgen receptor specific sequence, and composition for preventing hair loss and promoting hair growth comprising same
WO2025254047A1 (ja) * 2024-06-06 2025-12-11 東亞合成株式会社 アンドロゲン受容体 ｒｎａ配列に基づく新規二本鎖ｒｎａ及びその利用

Also Published As

Publication number Publication date
EP2591104A4 (en) 2014-09-03
US9732347B2 (en) 2017-08-15
CA2804210A1 (en) 2012-01-12
US20150197756A1 (en) 2015-07-16
WO2012006241A3 (en) 2012-04-19
US8927515B2 (en) 2015-01-06
EP2591104A2 (en) 2013-05-15
US20130131149A1 (en) 2013-05-23
WO2012006241A2 (en) 2012-01-12
AU2011276363A1 (en) 2013-01-10

Similar Documents

Publication Publication Date Title
US8927515B2 (en) Methods and compositions for the specific inhibition of androgen receptor by double-stranded RNA
JP5976643B2 (ja) 二本鎖ｒｎａによるベータ−カテニンの特異的阻害に対する方法と組成物
JP6010458B2 (ja) 非対称二本鎖ｒｎａによる特異的阻害のための、方法および組成物
US9670488B2 (en) Methods and compositions for the specific inhibition of met by double stranded RNA
JP2015529467A (ja) 二本鎖ｒｎａによるｍｙｃの特異的阻害に関する方法および組成物
JP2012528882A (ja) ペプチドダイサー基質剤およびその特異的な遺伝子発現阻害のための方法
WO2014093746A2 (en) Methods and compositions for the specific inhibition of ckap5 by double-stranded rna
US10011834B2 (en) Methods and compositions for the specific inhibition of HIF-1α by double-stranded RNA
HK40059743A (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
HK1227054B (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140625

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140625

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20160125